Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

PDF  |  How to cite

Oncotarget. 2018; 9:35283-35283. https://doi.org/10.18632/oncotarget.26252

Metrics: PDF 1196 views  |   ?  

Zexi Hu1,2,*, Yong Hu1,2,*, Xicheng Liu2, Rongwen Xi2, Aiqun Zhang3, Deruo Liu4, Qiang Xie5 and Liang Chen2,6

1 College of Life Sciences, Beijing Normal University, Beijing, China
2 National Institute of Biological Sciences, Beijing, China
3 The General Hospital of People’s Liberation Army (301 hospital), Beijing, China
4 Department of thoracic surgery, China-Japan Friendship Hospital, Beijing, China
5 Fuzhou Pulmonary Hospital of Fujian, Fujian, China
6 National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China
* Co-first author

Published: October 16, 2018

This article has been corrected: The correct Acknowledgment information is given below:


This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2015; 6:31628-31639. DOI: https://doi.org/10.18632/oncotarget.5221.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26252